Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHIMERIX INCCMRX · Entity 80651 | SVP, CFO & Secretary | May 22, 2019 | May 22, 2019 |
| Werewolf Therapeutics, Inc.HOWL · Entity 7244 | Chief Financial Officer | January 02, 2025 | January 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHIMERIX INC
Report date May 22, 2019 · Filed May 22, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 217,088 |
Reported balance
After 2019-05-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-05-22 · Tax withholding · Disposed 3,795 · Balance 217,088 F1: The shares were sold in payment of the reporting person's tax liability incurred upon the vesting of shares subject to a restricted stock unit award. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.40 to $3.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F3: Includes 6,353 shares acquired under the Issuer's Employee Stock Purchase Plan on March 8, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold in payment of the reporting person's tax liability incurred upon the vesting of shares subject to a restricted stock unit award.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.40 to $3.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3: Includes 6,353 shares acquired under the Issuer's Employee Stock Purchase Plan on March 8, 2019.
Werewolf Therapeutics, Inc.
Report date January 02, 2025 · Filed January 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.56 · Expires 2034-12-31 | Direct | 150,000 |
Reported balance
After 2025-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-02 · Grant · Acquired 150,000 · Balance 150,000 F1: The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in equal monthly installments over four years, with the initial vesting to commence on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.56 · Expires 2034-12-31 | Direct | 60,358 |
Reported balance
After 2025-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-01-02 · Grant · Acquired 60,358 · Balance 60,358 |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in equal monthly installments over four years, with the initial vesting to commence on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2025 Filed Jan 6, 2025 17:44 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 60,358 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0000950170-25-002344 · ownership.xml · derivative · entry 2 Trost Timothy W. · CIK 0001571865 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,358 Underlying: Common Stock · 60,358 shares Expires 2034-12-31 Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 17:44 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0000950170-25-002344 · ownership.xml · derivative · entry 1 Trost Timothy W. · CIK 0001571865 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-12-31 F1 · derivative.exercise_date: The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in equal monthly installments over four years, with the initial vesting to commence on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:40 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0000950170-24-001969 · ownership.xml · derivative · entry 1 Trost Timothy W. · CIK 0001571865 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-12-31 F1 · derivative.exercise_date: The option was granted on January 2, 2024 with a Vesting Commencement Date of January 1, 2024. The shares underlying the option vest in equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2028. Read SEC document |
| January 03, 2023 Filed Jan 9, 2023 21:35 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 102,800 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0000899243-23-001407 · doc4.xml · derivative · entry 1 Trost Timothy W. · CIK 0001571865 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,800 Underlying: Common Stock · 102,800 shares Expires 2032-12-31 F1 · derivative.exercise_date: The option was granted on January 3, 2023 with a Vesting Commencement Date of January 1, 2023. The shares underlying the option vest in equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2027. Read SEC document |
| January 06, 2022 Filed Jan 18, 2022 18:32 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 65,960 | $0.00 Strike: $11.55 | $0.00 |
DisclosureSEC source: 0000899243-22-002203 · doc4.xml · derivative · entry 1 Trost Timothy W. · CIK 0001571865 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,960 Underlying: Common Stock · 65,960 shares Expires 2032-01-05 F1 · derivative.exercise_date: The option was granted on January 6, 2022 with a Vesting Commencement Date of January 1, 2022. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the Vesting Commencement Date and 2.0833% of the shares vesting each month thereafter through January 1, 2026. Read SEC document |
| April 30, 2021 Filed May 4, 2021 16:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 54,756 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018113 · doc4.xml · derivative · entry 2 Trost Timothy W. · CIK 0001571865 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,756 Underlying: Common Stock · 54,756 shares Expires 2031-04-29 F2 · derivative.exercise_date: The option was granted on April 30, 2021. The shares underlying the option vest over four years in equal monthly installments through April 30, 2025. Read SEC document |
| February 12, 2021 Filed May 4, 2021 16:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 247,812 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0000899243-21-018113 · doc4.xml · derivative · entry 1 Trost Timothy W. · CIK 0001571865 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,812 Underlying: Common Stock · 247,812 shares Expires 2031-02-11 F1 · derivative.exercise_date: The option was granted on February 12, 2021 with a Vesting Commencement Date of February 8, 2021. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the Vesting Commencement Date and 2.0833% of the shares vesting each month thereafter through February 8, 2025. Read SEC document |
| May 22, 2019 Filed May 22, 2019 17:28 UTC | CHIMERIX INC CMRX · Entity 80651 | Tax withholdingCommon Stock | 3,795 | $3.44 | $13,065.81 |
DisclosureSEC source: 0001209191-19-032129 · doc4.xml · nonDerivative · entry 1 Trost Timothy W. · CIK 0001571865 · SVP, CFO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,088 F1 · shares: The shares were sold in payment of the reporting person's tax liability incurred upon the vesting of shares subject to a restricted stock unit award. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.40 to $3.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F3 · balance_after: Includes 6,353 shares acquired under the Issuer's Employee Stock Purchase Plan on March 8, 2019. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 19:12 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008279 · doc4.xml · nonDerivative · entry 1 Trost Timothy W. · CIK 0001571865 · SVP, CFO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,530 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the RSUs will vest in full on December 31, 2019. Read SEC document |
| January 29, 2019 Filed Jan 30, 2019 15:18 UTC | CHIMERIX INC CMRX · Entity 80651 | Tax withholdingCommon Stock | 2,588 | $2.20 | $5,693.60 |
DisclosureSEC source: 0001209191-19-005994 · doc4.xml · nonDerivative · entry 1 Trost Timothy W. · CIK 0001571865 · SVP, CFO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,530 F1 · shares: The shares were sold in payment of the reporting person's tax liability incurred upon the vesting of shares subject to a restricted stock unit award. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.20 to $2.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F3 · balance_after: Amount includes (i) 2,290 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (the "ESPP") on March 9, 2018 and (ii) 2,897 shares acquired pursuant to the ESPP on September 10, 2018 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 16:42 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantStock Option (Right to Buy) · Derivative | 176,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001209191-19-005361 · doc4.xml · derivative · entry 1 Trost Timothy W. · CIK 0001571865 · SVP, CFO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,000 Underlying: Common Stock · 176,000 shares Expires 2029-01-22 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 15:49 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantStock Option (Right to Buy) · Derivative | 141,750 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0001209191-18-005820 · doc4.xml · derivative · entry 1 Trost Timothy W. · CIK 0001571865 · SVP, CFO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,750 Underlying: Common Stock · 141,750 shares Expires 2028-01-24 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. Read SEC document |
| March 10, 2017 Filed Mar 31, 2017 16:55 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantCommon Stock | 5,186 | $4.10 | $21,247.04 |
DisclosureSEC source: 0001209191-17-023890 · doc4.xml · nonDerivative · entry 1 Trost Timothy W. · CIK 0001571865 · SVP, CFO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,931 F1 · timeliness: These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 24, 2017 Filed Jan 26, 2017 17:57 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantStock Option (Right to Buy) · Derivative | 50,750 | $0.00 Strike: $5.14 | $0.00 |
DisclosureSEC source: 0001209191-17-005780 · doc4.xml · derivative · entry 2 Trost Timothy W. · CIK 0001571865 · SVP, CFO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,750 Underlying: Common Stock · 50,750 shares Expires 2027-01-23 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. Read SEC document |
| January 24, 2017 Filed Jan 26, 2017 17:57 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantCommon Stock | 25,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-005780 · doc4.xml · nonDerivative · entry 1 Trost Timothy W. · CIK 0001571865 · SVP, CFO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,745 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs shall vest on January 24, 2018, 25% of the RSUs shall vest on January 24, 2019, 25% of the RSUs shall vest on January 24, 2020 and the remaining 25% of the RSUs shall vest on January 24, 2021. Read SEC document |
| September 09, 2016 Filed Sep 19, 2016 17:22 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantCommon Stock | 4,638 | $4.05 | $18,783.90 |
DisclosureSEC source: 0001209191-16-142041 · doc4.xml · nonDerivative · entry 1 Trost Timothy W. · CIK 0001571865 · SVP, CFO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,370 F1 · timeliness: These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.